AbbVie (ABBV) shares snapped eight consecutive sessions of losses as the stock closed up XYZ% at $XYZ. The North ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

JPMorgan lowered the firm’s price target on AbbVie (ABBV) to $200 from $210 and keeps an Overweight rating on the shares. While the ...

To battle those disruptions, AbbVie, maker of three migraine treatment options, launched a contest this year to provide support for people whose migraines create obstacles in reaching their ...

Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target The firm noted that AbbVie sounded ...

A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an ...

AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their ...

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine ...

For AbbVie, (NYSE: ABBV) it looks like some celebration is in order, because it just resolved one of its most pressing issues of the past few years. Here's how this drugmaker proved the bears ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

Johnson & Johnson (NYSE:JNJ) announced today more than 90 abstracts featuring data from the Company's differentiated blood cancer portfolio and pipeline will be presented at the 66th American Society ...